Regulatory T cells (Treg) play a major role in the suppression of protective anti-30 tumour T cell responses. In the CT26 BALB/c murine model of colorectal carcinoma, 31
Introduction 50 CD8+ T cell responses directed to tumours have been shown to occur in many human 51 cancers, where they are a positive prognostic indicator (1) (2) (3) (4) (5) . Backed by studies in 52 preclinical mouse models, which clearly show that CD8+ T cells are important in the 53 clearance of tumours and may confer lifelong protection against malignancy (6, 7), 54 immunotherapies aimed at boosting anti-tumour cytotoxic T lymphocytes (CTL) are 55
showing promise in the clinic. Naturally occurring responses can be initiated during 56 tumour growth to establish immunosurveillance in which a dynamic process of 57 immunoediting can ensue; immunological pressure from anti-tumour CTL balances 58 tumour elimination against the emergence of tumour escape variants with no 59 accompanying net outgrowth of tumour (8). This process is responsible for shaping 60 the immunogenicity of the tumour (9). Breakdown of this equilibrium leading to 61 tumour outgrowth involves multiple factors, including the balance between T cell 62 activatory (TcR engagement and co-stimulation) and inhibitory signals (exhaustion 63 markers and immunosuppressive cytokines), and evasion of the T cell response 64 through downregulation of antigen processing machinery or antigen loss. Therapeutic 65 approaches designed to tip the balance back in favour of tumour elimination by 66 providing activation agonists or blockade of inhibition is an attractive strategy that is 67 currently investigated (reviewed in (10)). FoxP3+ CD4+ regulatory T cells (Treg) are 68 important in establishing an immunosuppressive tumour microenvironment, and their 69 infiltration into tumours is a negative prognostic biomarker (11) and a significant 70 obstacle to successful immunotherapy, correlating with a poorer outcome in clinical 71 trials (reviewed in (12)). Therefore, Treg depletion as a therapeutic option is being 72 pursued in the clinic, based on studies in mice that showed rejection of transplanted 73 tumours following ablation of Treg with anti-CD25 antibodies (13, 14) . 74
One of the most widely used mouse models for preclinical testing of new 75 immunotherapeutic drugs is the transplantable BALB/c derived colorectal tumour 76 CT26 (15, 16) . In this model, we have shown that depletion of Tregs induces robust 77 protective anti-tumour immunity that effects tumour rejection in ~90% of mice, 78 similar to responses observed in other mouse tumour models (13, 17) . The CT26-79 immune mice developed memory CTL responses and were able to reject a second 80 challenge with CT26 as well as tumour lines of different histological origin following 81 recovery of Tregs to normal levels. Anti-tumour responses in these mice are focussed 82 on two epitopes derived from gp90; AH1 (SPSYVYHQF, (18)) and GSW11 83 (GGPESFYCASW, (17) ). The anti-GSW11 response is more sensitive to Treg 84 suppression in vivo, illustrated by the fact that functional (IFN-γ-producing) anti-85 GSW11 CTL can only be detected in tumour draining lymph nodes (tdLN) in the 86 absence of Treg whereas anti-AH1 CTL are detected whether or not Treg are present 87 (17). Anti-GSW11 CD8+ T cells deliver the most potent anti-tumour response 88 characterised by their ability to reject tumours expressing very low levels of antigen 89 (13, 17) . 90
To investigate the basis of differential suppression of the GSW11-specific T cell 91 response further, we utilised peptide-specific tetramers, to detect both functional 92 (IFN-γ + ) and inactivated (IFN-γ -) antigen-specific T cells. We show that in Treg 93 replete tumour-bearing mice GSW11-specific T cells made up the majority of CD8+ 94 tumour infiltrating lymphocytes (TIL), but exhibit an exhausted phenotype 95 characterised by PD-1 expression and absence of IFN-γ production upon stimulation. 96
We also found that Treg depletion permitted the proliferation of GSW11-specific T 97 cells with lower TcR/MHC avidity suggesting that this population may be more 98 efficacious at rejecting tumour than their higher avidity counterparts with the same 99 epitope specificity. 100 according to manufacturer's instructions. The transmembrane domain of H2-D d was 126 substituted for a biotinylation site using overlapping extension PCR. In addition, a 127 disulphide trap was incorporated into the construct (19) were tested for binding against the GSW11-specific T cell hybridoma, CCD2Z. For 143 the analysis of AH1-specific T cells, AH1-specific dextramers were used 144 (Immunodex). 145 146
Isolation and analysis of antigen-specific T cells and Tregs 147
Spleens, tumour draining lymph nodes and tumours from CT26 challenged mice 148 (Treg depleted or replete) were harvested between days 3-25 and disaggregated. 149 CD8+ T cell responses to CT26 antigens GSW11 and AH1 were assessed using 150 antigen-specific tetramers and the production of IFN-γ following peptide stimulation. 151 CD8+ T cells, APCs and peptides/tumours were cultured together for 4 hours in the 152 presence of brefeldin A (BD biosciences) before being stained for cell surface α-CD8 153 (63-6.7; BD biosciences), antigen-specific tetramer/dextramer, α-PD-1 (RMPI-30; 154 eBiosciences) and intracellular α-IFN-γ (XMG1.2; BD biosciences) using the 155 Cytofix/Cytoperm kit (BD biosciences) according to manufacturer's instructions. 156
Cells were enumerated by flow cytometry. Numbers reported are those above the 157 background response of T cells alone, with no peptide stimulation. Single cell CD8+ 158 lymphocytes were gated and assessed for tetramer binding and expression of For analysis of PD-1, CD8+ and tetramer+ were gated and assessed for PD-1 and 160 IFN-γ expression. Within these gates the T cell receptor clonality of GSW11-specific 161 T cells was assessed using a panel of 15 Vβ-specific antibodies (BD biosciences). 162
First, total CD8+ T cells were purified using a CD8 magnetic isolation negative 163 selection kit (Miltenyi) according to manufacturer's instructions. Purified CD8s were 164 stained with GSW11-specific tetramer, α-Vβ kit, α-CD8 and analysed by flow 165 cytometry. For the analysis of Tregs, cells were stained for cell surface α-CD4 (RM-166 4-5; BD biosciences), α-CD25 (7D4; BD biosciences), α-PD-1 and α-PD-L1 167 (10F.9G2; Biolegend) and intracellular staining with α-FoxP3 (FJK-16S; 168 eBiosciences). 169 170
Tetramer competition assay 171
Spleens and tumour draining lymph nodes were pooled from Treg depleted or replete 172 mice. CD8+ T cells were purified from disaggregated tissues using magnetic isolation 173 by negative selection (Miltenyi). Purified CD8+ T cells were incubated with 50 nM of 174 dasatinib (New England Biolabs) to prevent TcR internalisation before staining with 175 α-CD8, α-TCR β-chain (H57-597; Biolegend) and 5 µg of PE-labelled GSW11-176 specific tetramers. After two washes, cells were incubated with bleached tetramer at 177 varying ratios of the initial PE-labelled tetramers: 2.5µg, 5µg, 10µg or 20µg per test. 178
Bleached tetramers were tested for no/minimal PE-fluorescence before use. The β-179 chain TCR staining was included to confirm the decreasing levels of PE-staining was 180 due to the fluorescently labelled tetramer being out-competed and not due to TcR 181 internalisation. 182 183
Statistical analysis 184
Analyses were performed using Prism software (GraphPad, San Diego, CA). The p 185 values were calculated using either two way ANOVA with Dunnett's post-test or two-186 tailed unpaired t test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p <0.0001). Tumour infiltrating GSW11-specific CD8+ T cells are exhausted in Recent studies using mouse models have shown that many tumour infiltrating anti-194 tumour CD8+ T cells have an exhausted phenotype, characterised by PD-1 expression 195 and a failure to express cytokines IL-2, TNF-α and 21) . Little is known 196 about whether, or to what extent, development of this phenotype relates to T cell 197 specificity. Clearly, a relationship exists inasmuch as T cell activation via TcR is a 198 prerequisite for the induction of exhaustion (reviewed in (22)). Given our previous 199 observations of differential suppression of anti-CT26 responses with different 200 specificity (17), we sought to investigate the induction of exhaustion in both AH1 and 201 GSW11-specific CD8+ T cells in CT26 tumour bearing mice using antigen-specific 202 tetramers as specificity probes for T cell populations, independent of their functional 203 phenotype. Due to the poor binding affinity of GSW11 for H2-D d (17) we utilised 204 single chain trimer tetramers with GSW11 tethered to the binding groove using a 205 short linker polypeptide (19), allowing stable expression of GSW11-D d monomers. In 206 CT26 challenged Treg replete mice, GSW11-specific T cells were the most abundant 207 CD8+ T cell population in tumours, making up >50% of all CD8+ T cell infiltration 208 after 14 days of tumour challenge ( Figure 1A , B, C). However, similar to the situation 209 seen in many human cancers, these infiltrating CD8+ T cells do not confer protection, 210
and tumours continue to grow in these animals. The population of GSW11-specific T 211 cells was significantly larger than AH1-specific T cells, which constituted a maximum 212 of 20% of infiltrating T cells at later stages of tumour challenge (d17 and d22; Figure  213 1B, C). Notably, while the two T cell populations (anti-GSW11 and -AH1 CD8+ T 214 cells) made up the majority of tumour infiltrating CD8+ T cells (>60%) at later time 215 points (d14-22), they were in the minority in early anti-tumour responses (d7-10, 216 Figure 1C ). Thus, an initial broad-specificity polyclonal TIL response becomes 217 focussed on two gp90 derived epitopes during tumour growth ( Figure 1C ). We next 218 investigated the function, after ex vivo peptide stimulation, of GSW11-and -AH1 219 specific CD8+ T cells harvested from tumours during the course of the challenge. The 220 vast majority of GSW11-specific CD8+ T cells were unable to produce IFN-γ, with a 221 decrease in functional T cells as the tumour progressed ( Figure 1D , E). Most of the 222 AH1-specific T cells were also non-functional, although, consistent with earlier 223 studies showing their presence in tdLN and spleen (17), there were significantly more 224 functional AH1-specific T cells at d22 compared to GSW11 (around 6% compared to 225 <1% functional; Figure 1D , E). This minor population of functional tumour-specific T 226 cells were, however, unable to control tumour growth. 227
To investigate whether the lack of effector function in anti-tumour T cells correlated 228 with the expression of checkpoint molecules commonly associated with T cell 229 dysfunction in tumours, we assessed the expression of PD-1 on GSW11-and AH1-230 specific T cells following tumour challenge. The majority of non-functional (IFN-γ -) 231 tumour infiltrating T cells of both specificities expressed PD-1 indicating the 232 induction of an exhausted phenotype (50-80%; Figure 2A , B). Anti-GSW11 CD8+T 233 cells acquired the non-functional phenotype more rapidly and to a greater extent 234 compared to AH1-specific T cells. Thus, a greater proportion of GSW11-T cells were 235 PD-1 + IFN-γat the first time-point, d7 (p =<0.001), which was sustained throughout 236 tumour growth ( Figure 2B ). Interestingly, a proportion of the small number of 237 functional (IFN-γ + ) GSW11-and AH1-specific T cells also expressed PD-1, ranging 238 from ~10% for AH1-specific T cells at day 7 to ~80% of GSW11-specific T cells at 239 day 22 ( Figure 2C ), indicating that these T cells are both activated and functional. 240
These results indicate that tumour infiltrating GSW11-specific T cells are highly 241 susceptible to the induction of an exhausted phenotype. 242
243
The presence of regulatory T cells correlates with PD-1 expression on tumour 244 infiltrating lymphocytes. 245
The tumour microenvironment has been shown to play a crucial role in modulating 246
anti-tumour T cell responses in vivo (23, 24) with the presence of tumour-infiltrating 247
Tregs impacting negatively on tumour rejection (11). We therefore investigated the 248 effect of Treg on the induction of exhaustion in infiltrating CD8+ T cells. In a 249 temporal analysis of TIL, Tregs comprised around 15% of total CD4+ T cells at the 250 earliest time point examined (d7). This rose to ~25% by d10 where it remained for the 251 duration of the tumour challenge ( Figure 3A) . Interestingly, the accumulation of 252 Tregs in the tumour followed similar kinetics to that observed for the loss of effector 253 function in GSW11-specific T cells ( Figure 2B and 1D ). Most Tregs expressed PD-L1 254 in both tumour and the tumour draining LN (tdLN) from the earliest time-point 255 onwards ( Figure 3B ), suggesting that Treg suppression of GSW11-specific T cells 256 may be mediated via PD-1/PD-L1 interaction. Since tumour-specific T cells also 257 engage with tumour cells for activation, we examined the expression of PD-L1 on 258 tumour cells over 25 days following inoculation. In vitro CT26 expressed low levels 259 of PD-L1, however this increased significantly both in terms of the proportion of 260 CT26 expressing, and the level of expression following their seeding and growth in 261 vivo ( Figure 3C ). These results suggest that during initial stages of growth, the tumour 262 
Dysfunction of anti-tumour T cells is induced in the periphery 270
We next investigated whether GSW11-and AH1-specific T cells are primed 271 effectively to induce T cell effectors. Examination of naïve T cell populations 272 (GSW11 and AH1) showed that both expressed low levels of PD-1 (consistent with 273 previous studies; (25)) with expression on GSW11-specific T cells being slightly 274 greater than AH1-specific T cells ( Figure 4A ). Following CT26 seeding in Treg 275 replete mice we observed functional (IFN-γ producing) AH1-and GSW11-specific T 276 cells in spleen and tdLN, appearing at d3 and detectable through to the humane end 277 point at d22, with AH1-specific T cells dominating over GSW11-specific T cells at 278 later time points ( Figure 4B and C). AH1-specific responses were similar throughout 279 the experiment in lymphoid organs, with the greatest response in spleen ( Figure 4C ). 280
By contrast, GSW11-specific IFN-γ responses were greatest at early time points (d3-281 10) and declined over time ( Figure 4B ). This confirmed that a co-dominant, functional 282 (IFN-γ) response to AH1 and GSW11 was established in tdLN and spleen 283 immediately following tumour seeding in Treg replete mice and that over time, 284 progressive loss of functional anti-GSW11, but not anti-AH1-specific T cells, was 285 seen. In Treg depleted mice, in which tumours are rejected, GSW11-specific T cells 286
were dominant at most time points, in particular at time points d3-17, in both spleen 287 and tdLN with the greatest response observed in spleen (in line with our previous 288 observations (17) and Figure 4B and C). In addition, the magnitude of anti-GSW11 289 responses were much greater in Treg depleted compared to Treg-replete mice. AH1-290 specific responses became co-dominant after d17. Indeed, the magnitude of the anti-291 AH1 response was not sensitive to the presence or absence of Treg ( Figure 4C ). 292
Analysis of PD-1 expression on non-functional (IFN-γ -) T cells revealed that a 293 significant proportion (~20%) of GSW11-specific T cells in the spleen and tdLN 294 expressed PD-1 throughout the time-course, even at the earliest time-point of 3 days; 295 rising to ~40% at d22 in tdLN ( Figure 4D ). By contrast, only a very small proportion 296 of IFN-γ -AH1-specific T cells expressed PD-1, with a maximum of ~10% of cells in 297 tdLN reached by d22 ( Figure 4E) . A similar pattern of dysfunctional GSW11-and 298 AH1-specific T cells was observed in the spleens of tumour challenged Treg depleted 299 mice, although, there was a much greater reduction in GSW11-specific T cells 300 compared to AH1, illustrating the differential suppression of anti-CT26 T cells by 301
Tregs ( (17) and Figure 4D and E). Importantly, the proportion of dysfunctional 302 GSW11-specific T cells was significantly lower in tdLN of Treg depleted mice (d7 303 and d22; Figure 4D ), suggesting that Treg can exert their effect on T cells in tdLN and 304 spleen and their removal reduces the induction of dysfunction in tumour-specific T 305 cells following priming. 306
It is likely that the precursors of IFN-γ -, PD-1 + T cells are IFN-γ + , PD-1 + (22), 307 therefore, to gain a better understanding of the dynamics of transition from functional 308 to dysfunctional phenotypes we assessed PD-1 expression on functional (IFN-γ + ) 309 CD8+ T cells. In Treg replete mice, levels of PD-1 + IFN-γ + GSW11-and AH1-310 specific T cells were similar, although more AH1-specific T cells were observed at 311 later time points in spleens (d14-22; Figure 4F and G). Similar levels of PD-1 + IFN-γ + 312 GSW11-and AH1-specific T cells were observed in Treg depleted mice, however 313 more PD-1 + IFN-γ + GSW11-specific T cells were seen at d17 and d22 in spleens 314
( Figure 4F and G) . These results indicate that, although the level of primed functional 315 AH1-and GSW11-specific responses is similar, GSW11-specific T cells are more 316 susceptible to the induction of a dysfunctional phenotype. 317 318
Diversity of GSW11-specific T cell responses in Treg depleted mice 319
Previous studies have shown that the presence of Treg during priming to a 320 transplantation antigen inhibits the priming of T cells with low-avidity TcR (26). To 321 investigate this possibility in the context of Treg-dependent tumour rejection, we first 322 investigated the oligoclonality of the anti-GSW11 T cell response with a view to 323 identifying oligoclonal populations that are preferentially suppressed by Treg. To this 324 end, we determined TcR Vβ usage of GSW11-specific T cells from CT26 challenged 325
Treg replete mice using a panel of V-region specific antibodies. This revealed that the 326 anti-GSW11 response was very diverse with at least 15 different clonotypes observed 327
( Figure 5A and B) . Despite the broad response only three Vβ represented >10% of 328 GSW11-specific T cells (Vβ8.1/8.2, Vβ8.3 and Vβ14; Figure 5A 
Tregs target lower avidity anti-GSW11 T cells 340
We next estimated the TcR avidity of anti-GSW11 T cell oligoclones that were 341 preferentially suppressed by Treg (Vβ3 and Vβ13) compared to oligoclones that were 342 largely unaffected by the presence of Treg (Vβ8.1/8.2 and Vβ8.3), using tetramer 343 competition assays as described previously ( Figure 6A and (27) ). The two dominant T 344 cell oligoclones that expanded following Treg depletion, Vβ3 and Vβ13, had a lower 345 avidity compared to Vβ8.1/8.2 and Vβ8.3 T cells, which had similar populations 346 whether Tregs were present or not ( Figure 6B and C) . In addition, two oligoclones, 347
Vβ10b and Vβ14, which were proportionally better represented in Treg replete mice, 348 displayed a high avidity similar to that observed for Vβ8.1/8.2 and Vβ8.3 T cells 349
( Figure 6B and C). Levels of cell surface TcR β chain were similar regardless of the 350 amount of competing tetramer added (Supplementary figure 1) . This confirmed that 351 the reduction in tetramer staining was due to competition and not decreased TcR. In 352 pooled samples from groups of 3/4 mice, these low avidity T cells account for ~16% 353 of the total anti-GSW11 response in Treg depleted animals compared to ~2.5% in 354
Treg replete animals (red shades; Figure 5B ). In addition, high avidity T cells make 355 up >70% and ~55% of the total anti-GSW11 T cell response in Treg replete and 356 depleted mice respectively (blue shades; Figure 5B ). This indicates that sensitivity of 357 a T cell to Treg suppression might be linked to TcR avidity, with lower avidity T cells 358 preferentially targeted. Therefore, in the CT26 model, Treg depletion results in the 359 elaboration of a tumoricidal GSW11-specific T cell response, which appears to 360 correlate with preferential expansion of some low avidity GSW11-specific sub-clones. 361
The response in Treg depleted mice represents a 6-fold increase in low avidity TcR, 362 which make up ~1/6 of the GSW11-specific response compared to only 1/40 in Treg 363 replete mice. 364 365
Discussion 366
Immune surveillance of cancers starts with the priming of T cells to tumour associated 367 antigens (TAA) and their infiltration into the diseased tissue. Here, their anti-tumour 368 function is modulated by the evolving microenvironment, often leading to tumour 369 escape via multiple mechanisms including the induction of T cell tolerance/anergy 370 (through lack of co-stimulation during priming) or exhaustion (through the 371 progressive loss of effector function following activation) (22, 28). Using antigen-372 specific multimers, we show that, in a commercially important preclinical mouse 373 model, growing CT26 tumours are highly infiltrated with tumour-specific CTL 374 recognising one of two non-mutated epitopes (GSW11 and AH1) from a single highly 375 abundant TAA, gp90. Most TIL, however, exhibit an exhausted phenotype, which is 376 at least in part mediated by Tregs. 377
In human cancer, high levels of T cell infiltration generally correlate with good 378 prognosis. This infiltration is marked by a signature that includes increased 379 transcription of genes associated with antigen processing and presentation (MHC I 380 and MHC II), T cell markers (CD8, CD4, CD3) and genes associated with T cell 381 homing (CCL2, CCL3, CCL4, CXCL9, CXCL10 -the latter two being CD8+T-cell 382 specific), signalling (ICOS, IRF1) and CTL function (granzymes, IFN-γ) (29, 30) . 383
These are all consistent with the tumour milieu supporting ongoing peptide:MHC I 384 (pMHC I)-driven T cell proliferation via TcR engagement. However, because of their 385 secretion of the inflammatory cytokine IFN-γ, CD8+ TIL also drive evolution of the 386 immunosuppressive microenvironment including expression of PD-L1, IDO and the 387 infiltration of Tregs (31). In addition, T cells derived from highly infiltrated tumours 388 express the highest levels of inhibitory receptors (such as PD-1) (31). Immunotherapy 389 targets all three key stages of anti-tumour immunity: priming, infiltration and 390 regulation, and the gene signature for T cell inflamed (so-called 'hot') tumours 391 encompasses patterns of differentially expressed transcripts associated with positive 392 responses to checkpoint blockade immunotherapy (PD-1, PD-L1, CTLA4) (32). 393
The CT26 tumour microenvironment resembles cancers with a strong T cell 394 inflamed phenotype, and a signature that includes elevated transcripts for T cell 395 infiltration and activation, CD8, CD4, CD3, CD45, CD62L, CD80, CD86, CD40, 396 OX40L, CD25 and immunosuppression including FoxP3, . 397
Indeed, we show here that although the tumour mass is infiltrated with tumour-398 specific CD8+ T cells, they are functionally inert. Despite the obvious differences 399 between spontaneously arising cancer and a transplantable mouse model, studies that 400 have directly compared spontaneous and transplantable tumour models in mice have 401 found only small differences in the tumour-host interaction including immune gene 402 profiles (32, 33). Thus, our time-course of CT26 growth might reasonably 403 approximate to a model for the evolution of the tumour-immune interaction in 404 spontaneously arising cancers in terms of immune-editing and the development of 405 host immune modulation mechanisms within the microenvironment. This is 406 encouraging because transplantable models are more experimentally tractable and 407 permit a more rapid turnaround of preclinical immunotherapy studies. 408
With this in mind, we observed two key features of the CT26:BALB/c 409 interaction that are relevant to understanding human disease and its response to 410 immunotherapy. Firstly, Treg can differentially suppress different CTL clones 411 recognising TAA and this even applies to CTL recognising the same pMHC I 412 complex; and secondly that differential suppression of GSW11 and AH1-specific T 413 cells, characterised by upregulation of PD-1 expression and loss of effector function 414 (IFN-γ production) was observed very early after tumour challenge (d3) in tdLN. This 415 indicated that a large proportion of GSW11-specific CD8+ T cells were dysfunctional 416 at the site of priming. 417
The early preferential suppression of anti-GSW11 T cells persists in peripheral 418 tissues where a disparity between dysfunctional GSW11-and AH1-specific T cells is 419 evident in tdLN and spleen. By contrast, in tumours, the difference between GSW11 420 and AH1 T cells diminishes after d10. This difference between tdLN and tumour 421
indicates that there may be separate mechanisms that operate to establish T cell 422 dysfunction at the early priming and late effector phase. The differential induction of 423 dysfunction in GSW11 at early time points in tdLN, which is significantly reduced in 424 the absence of Tregs, suggests that Tregs play a key role in this process. The rapid 425 expression of PD-L1 on Tregs and PD-1 expression on GSW11-specific T cells 426 indicates this may be an important interaction. Indeed, stimulation of PD-1 (rapidly 427 upregulated following activation) by PD-L1 expressed on antigen presentation cells 428 can cause T cell anergy, defined by reduced proliferative capacity, in a peptide 429 induced model (34). The difference observed in PD-1 expression between AH1-and 430 GSW11-T cells may therefore be a reflection of the relative susceptibility to Treg 431 suppression at the priming stage mediated by PD-1/PD-L1 interaction. Once at the 432 tumour, there is much less difference between AH1 and GSW11 with respect to a 433 dysfunctional 'exhausted' phenotype. This change may be due to the increased 434 expression of PD-1 on AH1-T cells, similar to that observed on GSW11-T cells at the 435 tumour, due to continued antigenic stimulation (22). In addition, the more suppressive 436 microenvironment at the tumour site with PD-L1 expression on tumour cells as well 437
as Tregs, which accumulate over time, and the presence of immunosuppressive 438 cytokines such as TGF-β, may overcome any ability of AH1-specific T cells (and to a 439 lesser degree GSW11-T cells) to resist the induction of exhaustion. 440
The presence of Tregs in several cancer types is a negative prognostic 441
indicator. In addition, tumour-infiltrating Tregs have been shown to express gene 442 signatures, including markers of activation and function, which distinguish them from 443 not only blood Tregs, but also tissue resident Tregs from healthy tissue of the same 444 origin (35, 36) . Clinical trials are underway to determine the outcome of agents 445 designed to reduce Treg numbers by targeting the IL-2 receptor or GITR. To date 446 these results have been varied, with daclizumab (anti-CD25) reducing Treg numbers 447 in patients while allowing the induction of T cell responses to targeted tumour 448 antigens (37, 38) and a phase 1 trial of an anti-GITR antibody (TRX518) decreasing 449
Treg numbers in the tumour and circulating blood (39). However, depletion of Tregs 450 in stage IV melanoma with an IL-2/diphtheria toxin conjugate (DAB/IL-2) showed 451 partial responses in only 16.7% of patients, although there was a greater one year 452 survival in partial responders compared to those with progressive disease (80% vs. 453 23.7%; (40)). This study provides a fuller mechanistic framework for the further 454 rational development of Treg-targeted immunotherapy. Treg suppression of GSW11-455 specific T cells primarily affected those with lower avidity TcR. These clones 456 expanded in the absence of Tregs, and correlated with survival, suggesting they are 457 important in tumour rejection. It will be interesting to know whether these expanded 458 CTL have a similar profile to the recently described CD103+ CD8+TRM that 459 characterise T cell infiltrates of NSCLC associated with prolonged survival (41). The 460 expansion of protective low Ka T cell clones in Treg depleted mice is consistent with 461 previous studies. For example, Pace et al showed that the presence of Treg during 462 priming to a transplantation antigen increased the affinity of the CD8+ T cell response 463 by inhibiting the priming of T cells bearing low affinity TcR via a mechanism 464 involving CCL3/4 dependent destabilisation of T cell interactions with dendritic cells 465 (26). 466
The therapeutic efficacy of the low-avidity T cell clones was somewhat 467 unexpected since it is generally assumed that high avidity T cells have a competitive 468 advantage in an immune response due to stronger and prolonged activation signals 469 (42, 43) . However, in a situation of persistent antigenic stimulation, as is encountered 470 in the tumour, it is likely that these T cells progress to exhaustion as observed in 471 chronic viral infection. Low avidity CTL may escape the same fate through lower 472 expression of PD-1 or by receiving a TcR signal below the threshold required for 473 exhaustion while maintaining some effector function (44, 45) . 474
The identification of low Ka GSW11-specific TcR, which correlate with 475 protection, may have implications for epitope selection in immunotherapy. Current 476 strategies concentrate on the identification and use of tumour epitopes with a high 477 Ka/slow off-rate in an attempt to induce CD8+ T cell responses with a strong . This approach has had some success with antigen-specific T cell responses 479 directed to TAA such as NY-ESO-1 and MART-1 and neoantigens. However, only a 480 small proportion of these patients show a partial or complete clinical response (49, 481 50) . These studies show that, while the induction of high-avidity T cells to dominant 482 TAA occur, in a therapeutic setting, it may be more efficacious to induce a broad 483 repertoire of TcR affinities using peptide epitopes presented at sufficient levels 484 regardless of their affinity for MHC. With this in mind, it is notable that the dominant 485 target peptide recognised by TIL in CT26, GSW11, binds weakly to its presenting 486 MHC I, H2-D d with a half-life of ~20min at the cell surface, though it is presented in 487 high abundance (17). It will therefore be important to understand the relationship 488 between antigen processing/presentation and the induction of low avidity T cells. For 489 example, algorithms predicting the affinity of candidate peptides could be better 490 deployed for selecting candidate epitopes for targeted immunotherapy if used in 491 combination with computational models that take into account antigen abundance and 492 mechanistic details of the antigen processing pathway. 493 
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